PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2016.

Abstract The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents routinely receive tetanus, diphtheria, and acellular pertussis vaccine (Tdap), meningococcal conjugate vaccine (MenACWY), and human papillomavirus (HPV) vaccine (1) at age 11-12 years. ACIP also recommends catch-up vaccination with hepatitis B vaccine, measles, mumps, and rubella (MMR) vaccine, and varicella vaccine for adolescents who are not up to date with childhood vaccinations. ACIP recommends a booster dose of MenACWY at age 16 years (1). In December 2016, ACIP updated HPV vaccine recommendations to include a 2-dose schedule for immunocompetent adolescents initiating the vaccination series before their 15th birthday (2). To estimate adolescent vaccination coverage in the United States, CDC analyzed data from the 2016 National Immunization Survey-Teen (NIS-Teen) for 20,475 adolescents aged 13-17 years.* During 2015-2016, coverage increased for ≥1 dose of Tdap (from 86.4% to 88.0%) and for each HPV vaccine dose (from 56.1% to 60.4% for ≥1 dose). Among adolescents aged 17 years, coverage with ≥2 doses of MenACWY increased from 33.3% to 39.1%. In 2016, 43.4% of adolescents (49.5% of females; 37.5% of males) were up to date with the HPV vaccination series, applying the updated HPV vaccine recommendations retrospectively.(†) Coverage with ≥1 HPV vaccine dose varied by metropolitan statistical area (MSA) status and was lowest (50.4%) among adolescents living in non-MSA areas and highest (65.9%) among those living in MSA central cities.(§) Adolescent vaccination coverage continues to improve overall; however, substantial opportunities exist to further increase HPV-associated cancer prevention.
PMID
Related Publications

National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011.

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.

National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012.

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2015.

National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013.

Authors

Mayor MeshTerms
Keywords
Journal Title mmwr. morbidity and mortality weekly report
Publication Year Start




PMID- 28837546
OWN - NLM
STAT- MEDLINE
DA  - 20170824
DCOM- 20170828
LR  - 20170828
IS  - 1545-861X (Electronic)
IS  - 0149-2195 (Linking)
VI  - 66
IP  - 33
DP  - 2017 Aug 25
TI  - National, Regional, State, and Selected Local Area Vaccination Coverage Among
      Adolescents Aged 13-17 Years - United States, 2016.
PG  - 874-882
LID - 10.15585/mmwr.mm6633a2 [doi]
AB  - The Advisory Committee on Immunization Practices (ACIP) recommends that
      adolescents routinely receive tetanus, diphtheria, and acellular pertussis
      vaccine (Tdap), meningococcal conjugate vaccine (MenACWY), and human
      papillomavirus (HPV) vaccine (1) at age 11-12 years. ACIP also recommends
      catch-up vaccination with hepatitis B vaccine, measles, mumps, and rubella (MMR) 
      vaccine, and varicella vaccine for adolescents who are not up to date with
      childhood vaccinations. ACIP recommends a booster dose of MenACWY at age 16 years
      (1). In December 2016, ACIP updated HPV vaccine recommendations to include a
      2-dose schedule for immunocompetent adolescents initiating the vaccination series
      before their 15th birthday (2). To estimate adolescent vaccination coverage in
      the United States, CDC analyzed data from the 2016 National Immunization
      Survey-Teen (NIS-Teen) for 20,475 adolescents aged 13-17 years.* During
      2015-2016, coverage increased for >/=1 dose of Tdap (from 86.4% to 88.0%) and for
      each HPV vaccine dose (from 56.1% to 60.4% for >/=1 dose). Among adolescents aged
      17 years, coverage with >/=2 doses of MenACWY increased from 33.3% to 39.1%. In
      2016, 43.4% of adolescents (49.5% of females; 37.5% of males) were up to date
      with the HPV vaccination series, applying the updated HPV vaccine recommendations
      retrospectively.dagger Coverage with >/=1 HPV vaccine dose varied by metropolitan
      statistical area (MSA) status and was lowest (50.4%) among adolescents living in 
      non-MSA areas and highest (65.9%) among those living in MSA central cities.
      section sign Adolescent vaccination coverage continues to improve overall;
      however, substantial opportunities exist to further increase HPV-associated
      cancer prevention.
FAU - Walker, Tanja Y
AU  - Walker TY
FAU - Elam-Evans, Laurie D
AU  - Elam-Evans LD
FAU - Singleton, James A
AU  - Singleton JA
FAU - Yankey, David
AU  - Yankey D
FAU - Markowitz, Lauri E
AU  - Markowitz LE
FAU - Fredua, Benjamin
AU  - Fredua B
FAU - Williams, Charnetta L
AU  - Williams CL
FAU - Meyer, Sarah A
AU  - Meyer SA
FAU - Stokley, Shannon
AU  - Stokley S
LA  - eng
PT  - Journal Article
DEP - 20170825
PL  - United States
TA  - MMWR Morb Mortal Wkly Rep
JT  - MMWR. Morbidity and mortality weekly report
JID - 7802429
RN  - 0 (Chickenpox Vaccine)
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Measles-Mumps-Rubella Vaccine)
RN  - 0 (MenACWY)
RN  - 0 (Meningococcal Vaccines)
RN  - 0 (Papillomavirus Vaccines)
RN  - 0 (Vaccines)
RN  - 0 (Vaccines, Conjugate)
SB  - IM
MH  - Adolescent
MH  - Advisory Committees
MH  - Chickenpox Vaccine/administration & dosage
MH  - Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage
MH  - Female
MH  - Hepatitis B Vaccines/administration & dosage
MH  - Humans
MH  - Immunization Schedule
MH  - Male
MH  - Measles-Mumps-Rubella Vaccine/administration & dosage
MH  - Meningococcal Vaccines/administration & dosage
MH  - National Health Programs
MH  - Papillomavirus Vaccines/administration & dosage
MH  - Practice Guidelines as Topic
MH  - United States
MH  - Vaccination/*utilization
MH  - Vaccines/*administration & dosage
MH  - Vaccines, Conjugate/administration & dosage
EDAT- 2017/08/25 06:00
MHDA- 2017/08/29 06:00
CRDT- 2017/08/25 06:00
AID - 10.15585/mmwr.mm6633a2 [doi]
PST - epublish
SO  - MMWR Morb Mortal Wkly Rep. 2017 Aug 25;66(33):874-882. doi:
      10.15585/mmwr.mm6633a2.